{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,14]],"date-time":"2025-10-14T07:18:00Z","timestamp":1760426280187,"version":"3.41.2"},"reference-count":55,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T00:00:00Z","timestamp":1744588800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>In 2021 China enacted the Physician Law, which specifically outlines the legal requirements for off-label drug use in Article 29. Legislators, medical institutions, and judicial authorities all hoped that this new regulation would effectively reduce illegal off-label drug use. However, many violations still occurred in medical practice even after the enactment of the Physician Law, leading to judicial cases. This article examines the current state of off-label drug use in China, and the legal liability risks faced by medical institutions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This study investigates data from two main aspects: (1) judicial decisions related to off-label drug use; and (2) surveys associated with off-label drug use from medical institutions. Systematic literature search and descriptive data analysis was conducted in this paper.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>This article identifies three main forms of non-compliant off-label drug use: first, insufficient evidence-based justification; second, deficiencies in the informed consent process; and third, the lack of an internal review system. These are also the primary factors leading to legal liability for medical institutions.<\/jats:p><\/jats:sec><jats:sec><jats:title>Discussion<\/jats:title><jats:p>From a legal doctrinal perspective, the article concludes by elaborating on how each legal requirement should be met. Our research provides insights into the factors that lead to legal liability for off-label drug use and examines how physicians and medical institutions can avoid such liability.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fphar.2025.1547418","type":"journal-article","created":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:10:21Z","timestamp":1744603821000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Off-label drug use in China after the Physician Law (2021): legal challenges and solutions"],"prefix":"10.3389","volume":"16","author":[{"given":"Shenbao","family":"Liang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fanxian","family":"Cai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,4,14]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"707","DOI":"10.1701\/3696.36847","article-title":"Presto ma non troppo [Early but not too much.]","volume":"112","author":"Addis","year":"2021","journal-title":"Recenti Prog. Med."},{"key":"B2","first-page":"71","article-title":"FDA, off-label use, and informed consent: debunking myths and misconceptions","volume":"53","author":"Beck","year":"1998","journal-title":"Food Drug Law J."},{"year":"2015","key":"B3","article-title":"Case No. (2015) xi min chu zi No. 17794"},{"key":"B4","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1097\/01.blo.0000079323.41006.12","article-title":"Hierarchy of evidence: from case reports to randomized controlled trials","volume":"413","author":"Brighton","year":"2003","journal-title":"Clin. Orthop. Relat. Res."},{"article-title":"The key elements of off-label drug use within the framework of physician autonomy [Master\u2019s thesis]. [Shanghai]: University of Finance and Economics","year":"2024","author":"Cai","key":"B5"},{"key":"B6","doi-asserted-by":"publisher","first-page":"121","DOI":"10.12048\/j.issn.1674-229X.2024.02.007","article-title":"Investigation and evaluation of the off-label use of Lenvatinib","volume":"34","author":"Chen","year":"2024","journal-title":"Pharm. Today"},{"key":"B7","first-page":"99","article-title":"Legal risk analysis and suggestions for policy improvement of off-label use","volume":"43","author":"Ding","year":"2022","journal-title":"Shanghai Med. and Pharm. J."},{"key":"B8","first-page":"77","article-title":"Evaluation the use and its reasonableness of intravenous ummunoglobulin in the department of reproductive health and infertility in a maternal and child health hospital","volume":"22","author":"Du","year":"2024","journal-title":"J. China Prescr. Drug"},{"key":"B9","first-page":"79","article-title":"Evaluation of off-label drug use in obstetrics and gynaecology based on evidence-based medicine in a hospital","volume":"21","author":"Gao","year":"2023","journal-title":"J. China Prescr. Drug"},{"key":"B10","doi-asserted-by":"publisher","first-page":"270","DOI":"10.13664\/j.cnki.pcr.2024.03.020","article-title":"Analysis and management of off-label drug use in obstetrics department of Lianyungang maternal and child health hospital","volume":"32","author":"Gao","year":"2024","journal-title":"Pharm. Clin. Res."},{"key":"B11","first-page":"481","article-title":"Off-label drug use catalog","volume":"34","year":"2024","journal-title":"Pharm. Today"},{"year":"2016","key":"B12","article-title":"Case No. (2016) Yue 01 Min Zhong 7889"},{"key":"B13","doi-asserted-by":"publisher","first-page":"148","DOI":"10.15887\/j.cnki.13-1389\/r.2023.03.044","article-title":"Analysis of the use of montelukast sodium in the fourth quarter of 2021 in a tertiary hospital","volume":"16","author":"Hong","year":"2023","journal-title":"Chin J Clin. Ration. Drug Use"},{"key":"B14","doi-asserted-by":"publisher","first-page":"20","DOI":"10.13407\/j.cnki.jpp.1672-108X.2024.05.005","article-title":"Investigation and analysis of off-label drug use in pediatric outpatient of a hospital from 2021 to 2022","volume":"30","author":"Huang","year":"2024","journal-title":"J. Pediatr. Pharm."},{"key":"B15","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s12962-023-00461-9","article-title":"Successes and challenges of China\u2019s health care reform: a four-decade perspective spanning","volume":"21","author":"Jakovljevic","year":"2023","journal-title":"Cost Eff. Resour. Allocation"},{"key":"B16","doi-asserted-by":"publisher","first-page":"600","DOI":"10.3969\/j.issn.2095-9346.2023.06.008","article-title":"Investigation of off-label drug use in children and adolescents in a psychiatric hospital","volume":"36","author":"Jia","year":"2023","journal-title":"J. Psychiatry"},{"key":"B17","first-page":"1723","article-title":"The off-label use of drugs in pediatrics","volume":"3","author":"Kalko","year":"2021","journal-title":"Pharmacol. Online"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1013","DOI":"10.13493\/j.issn.1672-7878.2024.10-007","article-title":"Analysis of off-label use of Doxycycline in pediatric outpatient and emergency departments of a hospital","volume":"21","author":"Lao","year":"2024","journal-title":"Anti Infect. Pharm."},{"key":"B19","first-page":"81","article-title":"Investigation and evaluation of the off-label use of Anlotinib","volume":"36","author":"Li","year":"","journal-title":"Strait Pharm. J."},{"key":"B20","doi-asserted-by":"publisher","first-page":"101","DOI":"10.3969\/j.issn.1672-9463.2024.09.023","article-title":"Investigation and evaluation of the off-label use of durvalumab","volume":"26","author":"Li","year":"","journal-title":"MMJC"},{"volume-title":"Einwilligung in medizinische Behandlungen: Eine rechtsvergleichende Analyse nach schweizerischem und chinesischem Privatrecht","year":"2018","author":"Liang","key":"B22"},{"key":"B23","doi-asserted-by":"publisher","first-page":"619","DOI":"10.14009\/j.issn.1672-2124.2024.05.024","article-title":"Investigation on management status of off-label drug use in 146 medical institutions","volume":"24","author":"Lin","year":"2024","journal-title":"Eval. Analysis Drug-Use Hosp. China"},{"key":"B24","doi-asserted-by":"publisher","first-page":"34","DOI":"10.16690\/j.cnki.1007-9203.2024.20.042","article-title":"Survey and analysis of off-label use of traditional Chinese medicines in the pediatric department of our hospital","volume":"32","author":"Luo","year":"2024","journal-title":"J. Traditional Chin. Med. Manag."},{"key":"B25","first-page":"61","article-title":"Investigation on current situation of antidepressants combination and off-label drug use in adolescents with mental disorders in the hospital","volume":"22","author":"Lv","year":"2024","journal-title":"J. China Prescr. Drug"},{"key":"B26","doi-asserted-by":"publisher","first-page":"289","DOI":"10.3969\/j.issn.1673-5501.2017.04.010","article-title":"Current practice, management and awareness of pediatric off-label drug use in China \u2013 a questionnaire based cross-sectional survey","volume":"12","author":"Mei","year":"2017","journal-title":"Chin. J. Evid. Based Pediatr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.21037\/tp-24-198","article-title":"The implementation of the guideline for the management of pediatric off-label use of drugs in China: a cross-sectional study","volume":"13","author":"Meng","year":"2024","journal-title":"Transl. Pediatr."},{"key":"B28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.14009\/j.issn.1672-2124.2022.06.027","article-title":"Analysis of off-label use of 2000 outpatient anti-tumor drug prescriptions","volume":"22","author":"Meng","year":"2022","journal-title":"Eval. Analysis Drug-use Hosp. China"},{"key":"B29","doi-asserted-by":"publisher","first-page":"124","DOI":"10.3390\/children12020124","article-title":"Polypharmacy in pediatric palliative care: exploring discrepancies between physicians and pharmacists","volume":"12","author":"Mengato","year":"2025","journal-title":"Children"},{"year":"2017","key":"B30","article-title":"Case No. (2017) su 01 Min Zhong 8325"},{"key":"B31","first-page":"88","article-title":"Analysis of off-label drug use for inpatient in department of nephrology","volume":"20","author":"Quan","year":"2022","journal-title":"J. China Prescr. Drug"},{"key":"B32","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1001\/archinte.166.9.1021","article-title":"Off-label prescribing among office-based physicians","volume":"166","author":"Radley","year":"2006","journal-title":"Archives Intern. Med."},{"key":"B33","doi-asserted-by":"publisher","first-page":"e228","DOI":"10.1111\/apa.12924","article-title":"Unlicensed and off-label drug use: a prospective study in French NICU","volume":"104","author":"Riou","year":"2015","journal-title":"Acta Paediatr."},{"key":"B34","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1136\/bmj.312.7023.71","article-title":"Evidence-based medicine: what it is and what it isn\u2019t","volume":"312","author":"Sackett","year":"1996","journal-title":"BMJ"},{"key":"B35","doi-asserted-by":"publisher","first-page":"24","DOI":"10.3969\/j.issn.1006-4931.2024.15.007","article-title":"Investigation on off-label drug use for rheumatic immune diseases in a Hospital","volume":"33","author":"Shen","year":"2024","journal-title":"China Pharm."},{"key":"B36","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1186\/s12913-023-09293-y","article-title":"Judicial and legislative practice and related suggestions on off-label drug use in China","volume":"23","author":"Si","year":"2023","journal-title":"BMC Health Serv. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"87","DOI":"10.19577\/j.1007-4406.2024.02.002","article-title":"Investigation and analysis of off-label drug use of Chinese patent medicine in medical institutions of different levels","volume":"33","author":"Song","year":"2024","journal-title":"Chin. J. Clin. Pharm."},{"key":"B38","doi-asserted-by":"publisher","first-page":"87","DOI":"10.16690\/j.cnki.1007-9203.2023.11.098","article-title":"The application of pharmaceutical intervention in promoting the rationality of off-label use of Chinese medicines in gynecological department of primary hospitals","volume":"31","author":"Sun","year":"2023","journal-title":"J. Traditional Chin. Med. Manag."},{"year":"2016","key":"B39","article-title":"Case No. (2016) Lu 09 Min Zhong 2374"},{"key":"B40","first-page":"85","article-title":"Analysis of off-label drug use in dermatology outpatient department of a hospital","volume":"21","author":"Tan","year":"2023","journal-title":"J. China Prescr. Drug"},{"key":"B41","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s11017-020-09521-0","article-title":"Experiential knowledge in clinical medicine: use and justification","volume":"41","author":"Tonelli","year":"2020","journal-title":"Theor. Med. Bioeth."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.cdtm.2019.02.001","article-title":"Evidence-based medicine in China","volume":"2019","author":"Wang","year":"2019","journal-title":"Chronic Dis. Transl. Med."},{"key":"B43","first-page":"69","article-title":"Analysis of off-label medication for chronic diseases in a hospital in 2023","volume":"14","author":"Wang","year":"2024","journal-title":"Physician Online"},{"key":"B44","unstructured":"Study on off-label use of medicinal products in the European Union\n          \n          \n            \n              Weda\n              M.\n            \n            \n              Hoebert\n              J.\n            \n            \n              Vervloet\n              M.\n            \n            \n              Puigmarti\n              C. M.\n            \n            \n              Damen\n              N.\n            \n            \n              Langedijk\n              J.\n            \n          \n          \n          2017"},{"year":"2024","key":"B45","article-title":"Declaration of Helsinki \u2013 Ethical Principles for medical research involving human participants"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00228-014-1729-3","article-title":"Strategy to address innovative off-label medication use in China: Grading management","volume":"70","author":"Wu","year":"2014","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"B47","doi-asserted-by":"publisher","first-page":"1358","DOI":"10.7539\/j.issn.1672-2981.2024.05.040","article-title":"Off-label usage of immune checkpoint inhibitors in a cancer hospital","volume":"22","author":"Yan","year":"2024","journal-title":"Cent. South Pharm."},{"key":"B48","doi-asserted-by":"publisher","first-page":"901","DOI":"10.11655\/zgywylc2024.14.004","article-title":"Retrospective investigation and analysis of the off-label use of Tripterygium hypoglaucum hutch tablets in the treatment of oral mucosal diseases","volume":"24","author":"Yue","year":"2024","journal-title":"Chin. Remedies and Clin."},{"key":"B49","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.7501\/j.issn.1674-5515.2024.08.037","article-title":"Application analysis of evidence-based evaluation criteria for off-label drug use in obstetrics and gynecology outpatient department of the Third the People\u2019s Hospital of Bengbu","volume":"39","author":"Zhang","year":"2024","journal-title":"Drug and Clin."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.13286\/j.1001-5213.2024.16.15","article-title":"Status on management of off-label drug use in 415 hospitals of Guizhou Province: a cross-sectional survey","volume":"44","author":"Zhang","year":"","journal-title":"Chin. J. Hosp. Pharm."},{"key":"B51","doi-asserted-by":"publisher","first-page":"1519","DOI":"10.3870\/j.issn.1004-0781.2024.09.029","article-title":"Status investigation on management of off-label drug use in tertiary hospitals of Guizhou Province","volume":"43","author":"Zhang","year":"","journal-title":"Herald of Medicine."},{"key":"B52","first-page":"174","article-title":"Investigation of off-label medication use in pediatric inpatient prescriptions","author":"Zhang","year":"2024","journal-title":"FUER JIANKANG DAOKAN."},{"key":"B53","doi-asserted-by":"publisher","first-page":"3086","DOI":"10.7539\/j.issn.1672-2981.2024.11.041","article-title":"Evidence-based evaluation of off-label use of antineoplastic drugs in the gynecology department in a hospital","volume":"22","author":"Zhang","year":"2024","journal-title":"Cent. South Pharm."},{"year":"2021","key":"B54","article-title":"Civil judgment, case No. (2021) yu 01 Min Zhong 6881"},{"key":"B55","doi-asserted-by":"publisher","first-page":"119","DOI":"10.16690\/j.cnki.1007-9203.2023.01.041","article-title":"Investigation and analysis of off-label use of oral proprietary Chinese medicines in a dermatology hospital","volume":"31","author":"Zhong","year":"2023","journal-title":"J. Traditional Chin. Med. Manag."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/17512433.2022.2120468","article-title":"Management guideline for the off-label use of medicine in China (2021 Edition)","volume":"11","author":"Zuo","year":"2022","journal-title":"Expert Rev. Clin. Pharmacol."}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1547418\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,14]],"date-time":"2025-04-14T04:10:45Z","timestamp":1744603845000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2025.1547418\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,14]]},"references-count":55,"alternative-id":["10.3389\/fphar.2025.1547418"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2025.1547418","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2025,4,14]]},"article-number":"1547418"}}